Literature DB >> 23010710

Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?

Joyce Curvers1, Daan van de Kerkhof, An K Stroobants, Erik-Jan van den Dool, Volkher Scharnhorst.   

Abstract

The use of direct thrombin inhibitors (DTIs) for prophylactic or therapeutic anticoagulation is increasing because of the predictable bioavailability and short half-life of these DTIs. However, in certain situations, indication of the concentration is warranted. We investigated the effects of 3 DTIs (lepirudin, argatroban, and bivalirudin) in 6 pooled plasma specimens on routine coagulation assays (activated partial thromboplastin time [aPTT], prothrombin time [PT], and thrombin time [TT]) and dedicated DTI assays (Hemoclot, HemosIL, the ecarin clotting time, and a chromogenic ecarin clotting time) on 2 coagulation analyzers. We found routine tests to be nondiscriminative between concentrations of different DTIs in the aPTT. Moreover, for PT and TT, the responses for different DTIs differed. This was similar for ecarin clotting assays. The Hemoclot and HemosIL assays showed identical linear increases for all 3 DTIs. We conclude that dedicated calibrated assays based on a diluted TT (Hemoclot and HemosIL) appear to be the most suitable for monitoring purposes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010710     DOI: 10.1309/AJCPQOD9WFPEYY0H

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.

Authors:  Jacob T Beyer; Stuart E Lind; Sheila Fisher; Toby C Trujillo; Michael F Wempe; Tyree H Kiser
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

2.  Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.

Authors:  E Chaussade; O Hanon; C Boully; F Labourée; L Caillard; G Gerotziafas; J-S Vidal; I Elalamy
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 3.  Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Authors:  Helen Mani; Alexander Kasper; Edelgard Lindhoff-Last
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

Review 4.  The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Authors:  Dheeraj Goswami; Matthew DiGiusto; Rajeev Wadia; Sean Barnes; Jamie Schwartz; Diana Steppan; Kristen Nelson-McMillan; Richard Ringel; Jochen Steppan
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-01-21       Impact factor: 2.628

5.  Direct Thrombin Inhibitor Resistance and Possible Mechanisms.

Authors:  Maria Cardinale; Michael Ha; Michael H Liu; David P Reardon
Journal:  Hosp Pharm       Date:  2016-12

6.  Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.

Authors:  Matej Samoš; Lucia Stančiaková; Jela Ivanková; Ján Staško; František Kovář; Miroslava Dobrotová; Peter Galajda; Peter Kubisz; Marián Mokáň
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

7.  Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban.

Authors:  Beric Berlioz; Haya S Kaseer; Devang K Sanghavi; Pramod K Guru
Journal:  BMJ Case Rep       Date:  2020-01-07

Review 8.  New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness.

Authors:  Helen Mani; Edelgard Lindhoff-Last
Journal:  Drug Des Devel Ther       Date:  2014-06-17       Impact factor: 4.162

Review 9.  Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians.

Authors:  W Frank Peacock; Zubaid Rafique; Adam J Singer
Journal:  Emerg Med Int       Date:  2016-05-16       Impact factor: 1.112

Review 10.  Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Authors:  Oliver Grottke; James Aisenberg; Richard Bernstein; Patrick Goldstein; Menno V Huisman; Dara G Jamieson; Jerrold H Levy; Charles V Pollack; Alex C Spyropoulos; Thorsten Steiner; Gregory J Del Zoppo; John Eikelboom
Journal:  Crit Care       Date:  2016-04-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.